Residency · Residency · Nuclear Medicine

Radiopharmaceutical Chemistry Essentials

Fundamental Concepts

What Is a Radiopharmaceutical

A radiopharmaceutical is a radioactive compound used for either diagnostic imaging or targeted therapy. It consists of two functional components: the radionuclide, which provides the detectable emission (gamma rays or positrons for imaging, beta or alpha particles for therapy), and the pharmaceutical or carrier molecule, which determines where the compound goes in the body by targeting specific tissues, receptors, or metabolic pathways. Carrier molecules can be antibodies, peptides, small molecules, or colloids. In some cases, the radionuclide itself serves as both the label and the pharmaceutical, as with I-131 for thyroid imaging and therapy (iodine is naturally concentrated by the thyroid gland) or Xe-133 for ventilation studies.

Ideal Properties of a Diagnostic Radiopharmaceutical

The ideal diagnostic radiopharmaceutical emits gamma rays or positrons of appropriate energy -- 100 to 200 keV for SPECT imaging, 511 keV for PET -- without particulate emissions that would increase patient dose unnecessarily. Its half-life should be long enough to complete the imaging study but short enough to limit radiation exposure. In the body, it should achieve a high target-to-background ratio, meaning robust uptake in the organ of interest and rapid clearance from non-target tissues. The radiolabel must remain stable in vivo, without premature dissociation. Practical considerations matter as well: the compound should be safe, non-toxic, sterile, pyrogen-free, readily available, and affordable.

Specific Activity

Specific activity refers to the amount of radioactivity per unit mass of the compound, expressed in units such as GBq per micromole. A carrier-free preparation contains no stable isotope of the radionuclide at all, yielding the highest possible specific activity. A no-carrier-added preparation has no stable carrier intentionally introduced, so its specific activity approaches the theoretical maximum. A carrier-added preparation includes stable isotope deliberately, resulting in lower specific activity. High specific activity is critical for receptor-based imaging, because receptor binding sites are limited in number. If non-radioactive compound is present, it competes for those same binding sites, effectively blocking the radioactive tracer and reducing the imaging signal.

Radiolabeling Strategies

Direct Labeling

In direct labeling, the radionuclide binds directly to the pharmaceutical molecule without an intermediary. Examples include radioiodination of proteins through electrophilic or nucleophilic substitution at tyrosine residues (used with I-131 and I-123) and the use of Tc-99m pertechnetate for thyroid imaging, where no additional chemistry is needed because the pertechnetate ion is trapped by thyroid tissue directly. Direct labeling is simpler to perform but may alter the molecular properties of the pharmaceutical or prove unstable under physiologic conditions.

Chelation

Chelation uses a bifunctional chelating agent to form a stable coordination complex with a metal radionuclide. The chelator is conjugated to the targeting molecule -- a peptide, antibody, or other biomolecule -- creating a bridge between the radionuclide and the targeting moiety. Several chelators are commonly used in nuclear medicine. DTPA is an open-chain chelator used for In-111 labeling but is less thermodynamically stable than alternatives. DOTA is a macrocyclic chelator with high kinetic and thermodynamic stability, used for Ga-68, Lu-177, Y-90, and Ac-225. NOTA is another macrocyclic chelator whose smaller cavity is particularly well suited to Ga-68. HYNIC is used for Tc-99m labeling of peptides, and HBED-CC is the chelator in Ga-68 PSMA-11. As a general rule, macrocyclic chelators are superior to open-chain chelators for in vivo stability because their ring structure resists dissociation more effectively. The chelator must be chosen carefully so that it does not impair the binding affinity of the targeting molecule.

Prosthetic Group Labeling

Prosthetic group labeling is used primarily for attaching F-18 to biomolecules. Because F-18 cannot be directly attached to most peptides or proteins under the mild conditions needed to preserve biological activity, a small F-18-labeled molecule (the prosthetic group) is synthesized first and then conjugated to the biomolecule in a second step. An example is F-18-SFB (succinimidyl fluorobenzoate), which can be coupled to proteins. This approach is more complex and time-consuming, and it generally yields lower radiochemical yields than direct labeling methods.

Click Chemistry

Click chemistry represents an emerging radiolabeling strategy that uses bio-orthogonal reactions, such as azide-alkyne cycloaddition, to conjugate radionuclides to complex biomolecules. These reactions are fast, highly selective, and proceed in high yield under mild aqueous conditions. Click chemistry is increasingly used in research settings for F-18 and other radionuclides, and it holds promise for simplifying the synthesis of next-generation radiopharmaceuticals.

Quality Control of Radiopharmaceuticals

Radiochemical Purity (RCP)

Radiochemical purity is the percentage of total radioactivity present in the desired chemical form. It is determined by thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), or paper chromatography. The minimum acceptable RCP varies by product but is typically greater than 90 to 95%. Radiochemical impurities -- radionuclide in unwanted chemical forms -- include free Tc-99m pertechnetate (unbound Tc-99m), hydrolyzed-reduced Tc-99m (colloidal Tc-99m), and free F-18 fluoride in FDG preparations.

Radionuclidic Purity

Radionuclidic purity is the percentage of total radioactivity attributable to the desired radionuclide. Impurities arise from side reactions during production in cyclotrons or reactors, or from generator breakthrough. The most important example is Mo-99 breakthrough in Tc-99m generators, which is limited to no more than 0.15 microCi of Mo-99 per mCi of Tc-99m at the time of administration. Radionuclidic purity is assessed by half-life measurements and gamma spectroscopy.

Chemical Purity

Chemical purity refers to the absence of non-radioactive chemical contaminants. In Mo-99/Tc-99m generators, aluminum ion breakthrough from the alumina column must not exceed 10 micrograms per mL, tested with a colorimetric spot test. For cyclotron-produced PET radiopharmaceuticals, residual solvents such as ethanol and acetonitrile must be below specified limits.

Sterility and Pyrogenicity

All radiopharmaceuticals intended for injection must be sterile. Sterility testing is performed according to USP methods using either membrane filtration or direct inoculation. Bacterial endotoxin (pyrogen) testing uses the LAL (Limulus amebocyte lysate) assay, with a limit of less than 175 endotoxin units per volume for most radiopharmaceuticals.

pH, Particle Size, and Visual Inspection

Each product must fall within an acceptable pH range. Particle size is particularly important for Tc-99m MAA, where 90% of particles should measure 10 to 90 micrometers and none should exceed 150 micrometers. Particles that are too small pass through the pulmonary capillary bed without trapping, defeating the purpose of the study, while particles that are too large risk hemodynamic compromise. Visual inspection confirms clarity, appropriate color, and absence of particulate matter.

Key Radiopharmaceutical Categories

Tc-99m Agents

Tc-99m is the most widely used diagnostic radionuclide in nuclear medicine, emitting a 140 keV gamma ray with a 6-hour half-life. Most Tc-99m radiopharmaceuticals are prepared using kit-based formulations: Tc-99m pertechnetate from the generator is added to a lyophilized kit containing a reducing agent (stannous chloride) and the desired ligand. Examples include Tc-99m MDP for bone imaging, Tc-99m MAA for lung perfusion, Tc-99m sestamibi for cardiac perfusion and parathyroid imaging, Tc-99m DTPA for renal GFR assessment, Tc-99m MAG3 for renal tubular imaging, Tc-99m sulfur colloid for liver/spleen imaging and GI bleeding studies, and Tc-99m mebrofenin for hepatobiliary imaging.

PET Radiopharmaceuticals

PET tracers include F-18 FDG, a glucose analog produced by cyclotron with a 110-minute half-life; Ga-68 agents, produced by generator (Ge-68/Ga-68) or cyclotron with a 68-minute half-life; C-11 agents with a 20-minute half-life that require an on-site cyclotron; N-13 ammonia with a 10-minute half-life used for cardiac perfusion PET; and Rb-82, a generator-produced tracer (Sr-82/Rb-82) with a 76-second half-life also used for cardiac perfusion PET.

Therapeutic Radiopharmaceuticals

Therapeutic radiopharmaceuticals deliver cytotoxic radiation to target tissues. I-131 is a beta and gamma emitter used for thyroid therapy and MIBG therapy. Lu-177 is a beta emitter with an imageable gamma, enabling both therapy and post-therapy imaging, and is used in DOTATATE and PSMA therapy. Y-90 is a pure beta emitter used in microsphere radioembolization. Ra-223 is an alpha emitter that targets bone and is used for prostate cancer bone metastases. Ac-225 is an alpha emitter under investigation for emerging theranostic applications.

Radiopharmaceutical Stability

In Vitro Stability

The shelf life of a radiopharmaceutical is the time after preparation during which radiochemical purity remains acceptable. Several factors affect in vitro stability, including radiolysis (self-irradiation that generates free radicals), oxidation, temperature, pH, and light exposure. Radiolysis becomes more significant at higher activity concentrations and with longer storage times. To counteract radiolysis, stabilizers such as ascorbic acid and gentisic acid are added as free radical scavengers. The expiration time must always be checked before administering any radiopharmaceutical.

In Vivo Stability

Once injected, the radiolabel must remain attached to its carrier molecule within the biological environment. Transchelation -- the stripping of a metal radionuclide by competing endogenous chelators such as transferrin or albumin -- is a major concern. Macrocyclic chelators like DOTA and NOTA are kinetically more inert than open-chain chelators like DTPA, making them more resistant to transchelation in vivo. For F-18-labeled compounds, defluorination can release free F-18 fluoride, which deposits in bone and creates artifacts on imaging.

<image>A schematic diagram showing the three main radiolabeling strategies: (1) direct labeling with radioiodine attaching to a tyrosine residue on a protein, (2) chelation showing a DOTA chelator complexed with Lu-177 conjugated to a somatostatin analog peptide, and (3) prosthetic group labeling showing F-18 first attached to a small prosthetic molecule then conjugated to a larger biomolecule. Label each strategy with key advantages and limitations.</image>

<image>A quality control workflow diagram for Tc-99m radiopharmaceutical kit preparation. Show the steps: generator elution, pertechnetate QC (Mo-99 breakthrough assay with dose calibrator, Al breakthrough with colorimetric strip), kit reconstitution with pertechnetate plus stannous chloride reduction, radiochemical purity testing by TLC (showing separation of free pertechnetate, hydrolyzed-reduced Tc-99m, and bound Tc-99m complex), and final visual inspection. Include acceptance criteria at each step.</image>

<image>A comparison chart of common chelators used in nuclear medicine (DTPA, DOTA, NOTA, HYNIC, HBED-CC) showing their chemical structures, preferred metal radionuclides, thermodynamic stability, kinetic inertness, and clinical applications. Highlight the superiority of macrocyclic chelators (DOTA, NOTA) over open-chain chelators (DTPA) for in vivo stability.</image>

Clinical Pearls

Radiochemical purity must be checked before patient administration. Low RCP leads to non-target organ uptake -- for example, free pertechnetate causes unexpected thyroid and stomach uptake on a bone scan, which can be mistaken for pathology.

Mo-99 breakthrough is tested using a lead pig that shields the 140 keV Tc-99m gamma rays but allows the higher-energy Mo-99 gammas (740/780 keV) to pass through for detection. The regulatory limit is 0.15 microCi of Mo-99 per mCi of Tc-99m at the time of administration.

Stannous chloride (Sn2+) is the universal reducing agent in Tc-99m kits. Either excess or insufficient stannous ion causes labeling failure, so kit instructions regarding activity and volume must be followed precisely.

Macrocyclic chelators such as DOTA are preferred over open-chain chelators like DTPA for therapeutic radionuclides because they resist transchelation in vivo, maintaining the integrity of the radiopharmaceutical during the extended circulation time needed for therapy.

High specific activity is critical for receptor-targeted radiopharmaceuticals. Non-radioactive (cold) compound competes for the limited receptor binding sites, reducing image quality or therapeutic efficacy.

Radiolysis is a significant concern for high-activity therapeutic preparations. The addition of ascorbic acid or gentisic acid as free radical scavengers is standard practice to preserve radiochemical purity during storage.

F-18 FDG quality control includes radiochemical purity by TLC or HPLC, pH measurement, residual solvent analysis (acetonitrile and ethanol), radionuclidic identity by half-life determination, and sterility and endotoxin testing.

References

• Saha GB. Fundamentals of Nuclear Pharmacy. 7th ed. Springer; 2018.
• Vallabhajosula S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT. Springer; 2009.
• USP Chapter 825: Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging. United States Pharmacopeia; 2020.
• Banerjee SR, Pomper MG. Clinical applications of Gallium-68. Appl Radiat Isot. 2013;76:2-13.

Read this lecture as Markdown